An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals

This review presents a comprehensive overview on selected synthetic routes towards commercial drug compounds as published in both journal and patent literature. Owing to the vast number of potential structures, we have concentrated only on those drugs containing five-membered heterocycles and focuse...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumann, Marcus, Baxendale, Ian R, Ley, Steven V, Nikbin, Nikzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Beilstein-Institut 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107522/
https://www.ncbi.nlm.nih.gov/pubmed/21647262
http://dx.doi.org/10.3762/bjoc.7.57
_version_ 1782205232175906816
author Baumann, Marcus
Baxendale, Ian R
Ley, Steven V
Nikbin, Nikzad
author_facet Baumann, Marcus
Baxendale, Ian R
Ley, Steven V
Nikbin, Nikzad
author_sort Baumann, Marcus
collection PubMed
description This review presents a comprehensive overview on selected synthetic routes towards commercial drug compounds as published in both journal and patent literature. Owing to the vast number of potential structures, we have concentrated only on those drugs containing five-membered heterocycles and focused principally on the assembly of the heterocyclic core. In order to target the most representative chemical entities the examples discussed have been selected from the top 200 best selling drugs of recent years.
format Online
Article
Text
id pubmed-3107522
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Beilstein-Institut
record_format MEDLINE/PubMed
spelling pubmed-31075222011-06-06 An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals Baumann, Marcus Baxendale, Ian R Ley, Steven V Nikbin, Nikzad Beilstein J Org Chem Review This review presents a comprehensive overview on selected synthetic routes towards commercial drug compounds as published in both journal and patent literature. Owing to the vast number of potential structures, we have concentrated only on those drugs containing five-membered heterocycles and focused principally on the assembly of the heterocyclic core. In order to target the most representative chemical entities the examples discussed have been selected from the top 200 best selling drugs of recent years. Beilstein-Institut 2011-04-18 /pmc/articles/PMC3107522/ /pubmed/21647262 http://dx.doi.org/10.3762/bjoc.7.57 Text en Copyright © 2011, Baumann et al. https://creativecommons.org/licenses/by/2.0https://www.beilstein-journals.org/bjoc/termsThis is an Open Access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (https://www.beilstein-journals.org/bjoc/terms)
spellingShingle Review
Baumann, Marcus
Baxendale, Ian R
Ley, Steven V
Nikbin, Nikzad
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
title An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
title_full An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
title_fullStr An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
title_full_unstemmed An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
title_short An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
title_sort overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107522/
https://www.ncbi.nlm.nih.gov/pubmed/21647262
http://dx.doi.org/10.3762/bjoc.7.57
work_keys_str_mv AT baumannmarcus anoverviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals
AT baxendaleianr anoverviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals
AT leystevenv anoverviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals
AT nikbinnikzad anoverviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals
AT baumannmarcus overviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals
AT baxendaleianr overviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals
AT leystevenv overviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals
AT nikbinnikzad overviewofthekeyroutestothebestselling5memberedringheterocyclicpharmaceuticals

Ejemplares similares